Sera Labs offers 1,500 recombinant proteins

Published: 1-Jun-2010
Research & Development

Including cytokines, growth factors, chemokines, hormones, enzymes and viral antigens

Sera Laboratories International, a UK-based serum specialist, has developed more than 1,500 recombinant proteins for a variety of species including human, mouse, rat, porcine, bovine and chicken. The collection includes cytokines, growth factors, chemokines, hormones, enzymes and viral antigens.

Sera Lab’s recombinant proteins are mainly derived from bacterial systems and also include mammalian, yeast, insect and plant sources. All are rigorously tested to ensure excellent quality and biological activity.

With headquarters and storage in Haywards Heath, West Sussex and a cell culture research facility in France, Sera Lab offers a complete range of animal-based research products from a variety of origins. The company supplies laboratories in more than 30 countries worldwide, either directly or through distributors.

See more

You may also like

Sustainability

Free online course introduces fundamentals of SFC

Read more
Learn how SFC can improve efficiency and reduce environmental impact

Trending Articles

  1. Christian Mias to succeed Andreas Reisse as CEO of SCHOTT Pharma Executive with over 20 years of management experience to lead pharmaceutical packaging and delivery systems company
  2. DBV Technologies announces last patient visit completed in Phase III peanut allergy trial in children The Phase III VITESSE clinical trial of the VIASKIN Peanut patch in peanut allergic children aged 4-7 years remains on track for topline data in Q4 of this year
  3. Patient dies in CRISPR gene therapy trial The FDA has now placed Intellia Therapeutics' Phase III CRISPR trials on hold over raised liver enzymes
  4. EazeBio and UC Santa Cruz partner to launch instrument-free diagnostic platform for global health The pair will co-develop a lab-independent cortisol biosensor, delivering rapid, affordable and AI-guided diagnostics for stress, metabolic health and a range of global health applications
  5. Novartis’ next-generation malaria treatment GanLum hits Phase III target with 97% cure rate Phase III trial of KLU156 (ganaplacide/lumefantrine) shows high efficacy against drug-resistant malaria, with potential to block transmission and transform treatment across Africa

You may also like

Sustainability

Free online course introduces fundamentals of SFC

Learn how SFC can improve efficiency and reduce environmental impact
Sustainability

UK Invests £9.9m to turn recycled nuclear material into lead-212 cancer therapies

A new UK-wide programme will use recycled nuclear fuel to create sustainable lead-212 targeted alpha therapies, aiming to deliver next-generation precision cancer treatments for hard-to-treat tumours
Research & Development

OSE Immunotherapeutics gets positive IDMC recommendation to continue Phase III trial of Tedopi for lung cancer

The Independent Data Monitoring Committee has endorsed the ongoing pivotal Phase III ARTEMIA study evaluating Tedopi in HLA-A2–positive metastatic non-small cell lung cancer
Research & Development

American Cancer Society expands ACS ACTS programme to boost equity in cancer clinical trials nationwide

Leveraging trained specialists and AI-powered trial matching, the ACS ACTS programme helps patients, caregivers and providers navigate clinical trial options while addressing barriers to participation
Manufacturing

SU Puresonic ultrasonic sensor ensures precise hygienic flow measurement

Innovative design meets the highest standards in food, pharma, and water treatment
Research & Development

Akeso wins NMPA approval to trial first China-developed bispecific Alzheimer’s antibody

China’s NMPA has cleared Akeso to begin clinical trials of AK152, a bispecific antibody designed to improve brain penetration and enhance Aβ plaque clearance
Research & Development

Novartis’ next-generation malaria treatment GanLum hits Phase III target with 97% cure rate

Phase III trial of KLU156 (ganaplacide/lumefantrine) shows high efficacy against drug-resistant malaria, with potential to block transmission and transform treatment across Africa
Subscribe now